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Abstract
Recent studies show that more than one-third of U.S. adults (over 72 million
people) were obese in 2005–2006. This includes 33.3% of men and 35.3% of women.
Obesity is a primary factor in the development of metabolic syndrome, a condition that
places individuals at high absolute risk of mortality and morbidity. The use of a
nutritionally balanced diet aimed at weight reduction has the potential to decrease the
prevalence of obesity, therefore reducing the incidence of metabolic syndrome and its
consequences.
The purpose of this project was to investigate whether individual nutrition
counseling would improve the outcomes of patients with metabolic syndrome. A transdisciplinary team of faculty and graduate students from nutrition and nursing served as
consultants and educators at a clinic for the uninsured in a southeastern city in the United
States. This study was a one-group before-and-after design, with baseline data obtained
on patients prior to the practice change. The study ran for six months. The intervention
was an evidence-based practice change incorporating intensive dietary program for 19
patients with metabolic syndrome and an evaluation of the effect of that change on
lipoproteins, glucose, blood pressure, weight, and waist circumference.
Although there were no positive changes in weight or waist circumference, the
participants did enjoy a significant decrease in blood pressure, fasting glucose and plasma
lipids. None of these changes were significantly associated with the dietary intervention.
Based on the most current evidence, the most effective way to reduce risks associated
with metabolic syndrome is weight reduction, adequate nutrition, and exercise.

Chapter One: Introduction
Cardiovascular disease is a major cause of morbidity and mortality in the U.S.
(Rosamond, 2007) and prevention, and treatment has been at the center of scientific
research for many years. As risk factors for cardiovascular disease were identified, it
became clear that more than one risk factor tended to occur in individuals. Obesity, type
2 diabetes, dyslipidemia, and hypertension are often present in individuals with
cardiovascular disease. This cluster of risk factors became known as “syndrome X,”
“insulin resistance syndrome,” and, the most widely and currently accepted term,
“metabolic syndrome” (Reaven, 1988).
In 1997, the World Health Organization (WHO) published a landmark document
recognizing obesity as a worldwide disease that poses a serious threat to public health
(Mokdad et al., 1999). Persons who are overweight or obese have a substantially
increased risk for morbidity from numerous chronic disorders, such as diabetes,
hypertension and cardiovascular disease. “Adults aged 40–59 had the highest obesity
prevalence compared with other age groups. Approximately 40 percent of men in this age
group were obese, compared with 28 percent of men aged 20–39, and 32 percent of men
aged 60 and older. Among women, 41 percent of those aged 40–59 were obese compared
with 30.5 percent of women aged 20–39” (Ogden, Carroll, McDowell, & Flegal, 2007, p. 2).
The latest data from the Centers’ for Disease Control (CDC) (2008) indicate that nearly
36% of black Americans, about 29% of Hispanics, and 24% of whites are obese.
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According to the National Cholesterol Education Program (NCEP) panel, metabolic
syndrome will soon have a greater impact on premature coronary artery disease than
tobacco (Third Report, 2001). However, traditional risk factors, including metabolic
syndrome, cannot explain the greater health burden of disease seen in obese African
Americans. Thus, it is imperative to identify additional risk factors that may contribute to
disease development or identify early indication of disease and examine the effect of
lifestyle and dietary management programs on these risk factors.
Metabolic syndrome is a grouping of risk factors that, when three or more are
present, increase a person’s risk for developing diabetes and heart disease. These risk
factors include insulin resistance, obesity, hyperlipidemia, hyperglycemia, and
hypertension (Grundy, Brewer, Cleeman, Smith & Lenfant, 2004). However, further
examination of the criteria by which the metabolic syndrome is diagnosed revealed that
these criteria differ depending on who established them (Grundy et al., 2005).
In 1998, the World Health Organization (WHO) developed a consensus definition
of metabolic syndrome. This was followed by definitions by the European Group for the
Study of Insulin Resistance (EGIR) in 1999, the third Adult Treatment Panel of the
National Cholesterol Education Program (NCEP-ATP III) in 2001 and the American
Association of Clinical Endocrinologists (ACCE) in 2003.
The International Diabetes Federation (IDF), in a global consensus statement,
presented a new, clinically accessible definition of the metabolic syndrome, representing
the views of experts in the fields of diabetes, cardiology, lipidology, public health,
epidemiology, genetics, metabolism, and nutrition from six continents (Grundy, Brewer
et al. (2004). According to the IDF 2005 definition, for a person to be defined as having
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the metabolic syndrome the person must have central obesity (defined as waist
circumference ≥ 94 cm for men and ≥ 80 cm for women) plus any two other risk factors.
The NCEP-ATP III definition from 2001 was revised in 2005 and is based on any three
risk factors. Similarly, the American Heart Association (AHA) and the National Heart,
Lung, and Blood Institute (NHLBI) base their definition on the presence of three risk
factors. Table 1.1 presents the evolution of the various definitions.
Evidence-based obesity treatment and medical nutrition therapy for obesity
related chronic diseases such as metabolic syndrome includes individualized counseling.
This is designed to increase knowledge and skills to improve adherence to healthy
behaviors including the adoption of a diet rich in whole grains, fruits and vegetables, and
a physically active lifestyle (Emili, Abushomar, & Nair, 2007).
The Extent of the Problem
It is difficult to determine the prevalence of metabolic syndrome worldwide
because of the differing criteria used to identify the condition (Ford, 2004). The IDF
suggests that the data presented from the third National Health and Nutrition Examination
Survey (NHANES III) surveys are a good estimation of the worldwide prevalence (IDF,
2007). Findings from NHANES III suggest that 24% of American men and 23% of
American women, or about 47 million people, have metabolic syndrome (see Table 1.2).
These data were compiled in 2002, but recent statistics may be even higher. It has been
reported that the prevalence of metabolic syndrome increases with age and its prevalence
among Americans over the age of 60 is 42–43.5%. Mexican Americans were found to
have the highest prevalence of metabolic syndrome at 31.9%. White Americans and
African Americans had the lowest prevalence at 23.8% and 21.6%, respectively.

Table 1.1 Criteria Proposed for Clinical Diagnosis of Metabolic Syndrome
Clinical measure

WHO (1998)

EGIR (1999)

ATP III (2001)

AACE (2003)

ATP III (2004)

IDF (2005)

Insulin resistance

IGT, IFG,
T2DM, or
lowered insulin
sensitivity plus
any two of the
following:
Men waist to hip
ratio > 0.90
Women waist to
hip ratio > 0.85,
or BMI > 30
kg/m2
TG ≥ 1.7
mmol/L and/or
HDL-C < 0.91
mmol/L

Plasma insulin >
75th percentile
plus any two of
the following:

None, but any
three of the
following five
features:

IGT or IFG plus
any of the
following based
on clinical
judgment:

None, but any
three of the
following five
features:

None

Waist
circumference
(WC) ≥ 94 cm

WC
Men ≥ 102 cm
Women ≥ 88 cm

BMI ≥ 25 kg/m2

WC
Men ≥ 102 cm
Women ≥ 88 cm

Increased WC
Men > 94 cm
Women > 80 cm
plus any two of
the following:

WC
Men ≥ 102 cm
Women ≥ 88 cm

TG ≥ 2.0
mmol/L and/or
HDL-C <1.01
mmol/L or
treated for
dyslipidemia
≥ 140/90 mm Hg
or on
hypertension Rx

TG ≥ 1.69
mmol/L, HDL-C
< 1.03 mmol/L

TG ≥ 1.69
mmol/L and
HDL-C < 1.03
mmol/L

TG ≥ 1.69
mmol/L, HDL-C
< 1.03 mmol/L

TG ≥ 1.7
mmol/L or on
TG Rx, HDL-C
< 1.03 mmol/L
or on HDL-C Rx

TG ≥ 1.69
mmol/L or on
TG Rx, HDL-C
< 1.03 mmol/L
or on HDL-C Rx

≥ 130/85 mm Hg

≥ 130/85 mm Hg

≥ 130/85 mm Hg

≥ 130 mm Hg
systolic or ≥ 85
mm Hg diastolic
or on
hypertension Rx

≥ 130 mm Hg
systolic or ≥ 85
mm Hg diastolic
or on
hypertension Rx

IGT or IFG (but
not diabetes)

> 6.11 mmol/L
(includes
diabetes)

IGT or IFG (but
not diabetes)

> 5.6 mmol/L
(includes
diabetes)

≥ 5.6 mmol/L
(includes
diabetes)

≥ 5.6 mmol/L or
on hypoglycemic

Body weight

Lipids

≥ 160/90 mm Hg

Glucose

IGT, IFG, or
T2DM

Other

mALB > 30 mg
creatinine

4

BP

AHA/NHLBI
(2005)
None, but any
three of
following five
features:

Table Deleted
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African American and Mexican American women had a greater prevalence of metabolic
syndrome than the men of the same ethnicity (Gami et al., 2007).
Currently there are no data for the prevalence of metabolic syndrome in the state
of Florida or Duval County. According to self-reported Behavioral Risk Factor
Surveillance System (BRFSS) data, 55.8% of Florida adults are overweight or obese,
which approximates to 7 million residents (Florida Department of Health [DOH], 2001).
Of these, 18.8% or nearly 2.5 million people are obese, with a body mass index (BMI) ≥
30. The 2001 BRFSS survey reported that the prevalence of being overweight among
adult men and women in Florida has increased by 58% since 1986, and the prevalence of
obesity has increased by 93% since 1986 (CDC, 2002) .
Treatment
The primary goal of clinical management of metabolic syndrome is to reduce risk
for clinical atherosclerotic disease. Weight reduction and increased physical activity are
first-line therapies for metabolic syndrome. Drug therapy is recommended when lowdensity lipoprotein cholesterol (LDL-C) is not lowered sufficiently by lifestyle
modifications.
Purpose
The purpose of this project was to investigate whether an intensive dietary
program including individual nutrition counseling would improve the outcomes of
patients with metabolic syndrome in an uninsured population.
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Definition of Terms
Metabolic syndrome. For the purposes of this study, the NCEP-ATP III (2002)
criteria will be used (see Table 1.3).

Table Deleted

Intensive dietary program. The individualized diet program will be based on the
Therapeutic Lifestyle Changes (TLC) diet. It is targeted to people whose LDL
cholesterol is above the goal level for their category of risk for heart disease. These are
the essential components of TLC diet (see Table 1.4).
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Dietary intake was assessed using the single 24-hour recall method by graduate
nutrition interns. Before testing, all subjects were instructed to maintain their usual
dietary habits. In this study, the daily energy intake and percentages of the ADA food
pyramid groups.
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Chapter Two: Literature Review
This chapter presents an overview of the search strategies used for identification
and retrieval of the evidence. This is followed by a brief overview of cardiovascular
disease and a review of the evidence with respect to the effects of metabolic syndrome on
cardiovascular disease. A discussion of the relationship between socioeconomic position
and metabolic syndrome is followed by a synthesis of the evidence for the use of the
Mediterranean and TLC diet. Evidence for non-pharmacologic measures for the treatment
of metabolic syndrome is also addressed.
Search Strategies
For this review, the following databases were searched: The Cochrane Library,
(inception to March, 2008), MEDLINE (inception to March, 2008), OVID (inception to
April, 2008), CINAHL (March, 2008), and MD Consult (inception to April, 2008). There
were no language restrictions for either searching or trial inclusion. The search strategy
below was used and adapted to suit the individual databases. Specific journals cited most
frequently included Annals of Internal Medicine, Circulation, Heart, Diabetic Medicine,
and The Journal of the American Dietetic Association. Keywords used included:
metabolic syndrome, obesity, and dietary factors. Searches were limited to randomized,
controlled trials (RCT) and meta-analyses conducted with human subjects investigating
the treatment of metabolic syndrome. In addition, a manual search of citations from
relevant original studies and review articles was performed. The final search produced
one recent Cochrane Review, three recent meta-analyses, one Agency for Healthcare
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Research and Quality (AHRQ) guideline and six randomized controlled trials (RCTs).
The search was then updated through examining references from meta-analyses and
review articles.
Metabolic Syndrome and Cardiovascular Disease
According to the AHA, (2007), more than 1 million Americans would suffer a
first or recurrent coronary event and nearly 500,000 of these would result in death.
Cardiovascular disease is the leading cause of death for both men and women, and its
prevalence increases with age. Despite known lifestyle changes and risk-factor
modification with pharmacologic and non-pharmacologic therapies, many patients are
still at risk for a cardiac occurrence.
There is strong evidence to suggest that metabolic syndrome doubles the risk for
cardiovascular disease and raises the risk for diabetes and mortality fivefold over a 5- to
10-year period (Greenstone, 2008). The data supporting this relationship are outlined in
Table 2.1.
Data from NHANES III (2006) were used to examine the frequency and
clustering of the risk factors that make up the metabolic syndrome. From the 12,332
subjects aged 30–74 years in the NHANES sample, this study identified 1,513 who were
free of diabetes and met the definition of the metabolic syndrome. When compared to the
U.S. population, this represents a sample of 16.5 million persons with metabolic
syndrome. This study demonstrated that the most common components of the metabolic
syndrome (present in more than 75% of subjects) were increased waist circumference (>
40 inches in men and > 35 inches in women), high BP (≥ 130/85 mm Hg), high
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triglycerides (≥ 150 mg/dL), and low HDL-C (≤ 40 mg/dL in men and ≤ 50 mg/dL in
women). Impaired fasting glucose (≥ 110 mg/dL), the least common risk factor, was
evident in 22% of men and 17% of women (Grundy et al., 2005).
Gami et al. (2007) performed a meta-analysis of longitudinal studies that assessed
any cardiovascular event outcomes or mortality in people with three or more coronary
risk factors (regardless of whether this was termed the metabolic syndrome) compared
with people without the diagnosis of metabolic syndrome. A total of 37 cohort studies
from 1971 to 1997 including 172,573 individuals were included. This meta-analysis
showed patients with metabolic syndrome had a relative risk (RR) of cardiovascular
events and death of 1.78 (95% confidence interval [CI] 1.58, 2.00). The association was
stronger in women (RR 2.63 vs. 1.98, p = 0.09), in studies enrolling lower risk
individuals (RR 1.96vs. 1.43, p = 0.04), and in studies using the WHO definition (RR
2.68 and 2.06 vs. 1.67 for National Cholesterol Education Program definition and 1.35
for other definitions; p = 0.005). The association remained after adjusting for traditional
cardiovascular risk factors (RR 1.54, 95% CI, 1.32, 1.79). The population of patients in
this trial was probably heterogeneous in that the review included studies of overweight
patients aged over 18 years. There was little description of the patients in the individual
studies.
Gami et al. (2007) found that (a) definitions of metabolic syndrome based on
factor analysis were far more predictive of cardiovascular events and death than were
other definitions; (b) the WHO-based criteria were better than NCEP-based criteria in
predicting cardiovascular events and death; and (c) the substitution of BMI for waist
circumference or waist-to-hip ratio in these criteria did not appear to affect their

13
outcomes. Inclusion and reporting biases in the RCTs may have limited the assessment
of the efficacy of lowering LDL concentration in diabetic patients without coronary heart
disease. Most trials of lipid lowering interventions for primary prevention of coronary
heart disease excluded diabetic patients by varied and ambiguous criteria.
A meta-analysis by Galassi, Reynolds, and He (2006) included a total of 21
prospective cohort studies. Among the 21 studies, 11 were conducted in the U.S. and 10
in Europe. The number of subjects ranged from 318 to 19,223. The ATP III criteria were
used in 16 studies, and the WHO criteria were used in 5. Two studies used both criteria.
The RR of cardiovascular disease associated with the metabolic syndrome in each study
and overall is > 1.0 and all but five were statistically significant. Individuals with the
metabolic syndrome had an overall RR of cardiovascular disease of 1.61 (95% CI, 1.42,
1.83) compared with individuals without the metabolic syndrome, Prevalence of the
metabolic syndrome varied from 8.8% to 92.3%. However, the highest prevalence of the
metabolic syndrome (75.6–92.3%) was observed in the three studies in which all study
participants had type 2 Diabetes.
A significant increase in the risk of cardiovascular disease associated with the
metabolic syndrome was found when data were analyzed according to sex, length of
follow-up, study country, and history of cardiovascular disease at baseline (Galassi et al.,
2006). The RR was higher among women compared with men and those studies with
follow-up that was longer than five years. Compared with the overall analysis, the RR
was slightly reduced in studies that were conducted on non diabetic patients. The metaanalysis indicated that individuals with metabolic syndrome have a 61% increased risk of
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cardiovascular disease compared with individuals without the metabolic syndrome
(Galassi et al., 2006).
Many experts believe that early and efficient identification of patients with
metabolic syndrome is important and that it is essential to use more advanced short-term
risk assessments such as those used in the Framingham Study. Grundy et al. (2005)
clearly states that these are the tools that should be used for short-term risk assessment.
The Framingham Risk Score (FRS) was derived from the Framingham Heart Study, and
is the most commonly recommended tool in the U.S. for global risk assessment in the
primary prevention setting (Ingelsson et al., 2007). Short-term absolute risk, defined as
the probability of a person developing a hard CHD endpoint (myocardial infarction or
cardiac death) in the next 10 years, can be estimated by calculating the number of
Framingham points assigned to each graded risk (see Table 2.2). At least three recent
studies have compared the short-term predictive value of the metabolic syndrome criteria
with that of the FRS (Obunai, Jani & Dangas, 2007).
There is evidence to suggest that abdominal obesity is an independent risk factor
for the development of diabetes, hypertension, hyperlipidemia and cardiovascular disease
in individuals with BMI < 35 (Carr & Brunzell, 2004). Abdominal obesity is also
associated with the metabolic syndrome. Measurement of waist circumference is the
simplest clinical method to detect abdominal obesity.
Katzmarzyk, Janssen, Ross, Church & Blair (2006) compared the predictive
ability of the NCEP-R and IDF metabolic syndrome criteria for mortality risk, and
examined the effects of waist circumference on mortality within the context of these
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criteria. Their sample included 20,789 White, non-Hispanic men aged 20–83 from the
Aerobics Center Longitudinal Study. “The study concluded that waist circumference is a
valuable component of metabolic syndrome. However, the change in the IDF definition
of metabolic syndrome of an elevated waist circumference warrants caution given that a
large proportion of men with normal waist circumference have multiple risk factors and
an increased risk of mortality” (p. 406).
General Treatment Strategies for Metabolic Syndrome
The primary goal of clinical management of metabolic syndrome is to reduce risk
for clinical atherosclerotic disease. The NCEP guidelines recommend a two-pronged
approach to clinical management of the metabolic syndrome: (a) reversing underlying
lifestyle causes, such as obesity, atherogenic diet, and physical inactivity; and (b) treating
associated non-lipid and lipid risk factors (NCEP Expert Panel, 2002). Weight reduction
and increased physical activity are first-line therapies for metabolic syndrome. Obesity,
hypertension, hyperlipidemia and type 2 Diabetes may mask underlying metabolic
syndrome, which is characterized by atherogenic dyslipidemia, elevated blood pressure,
insulin resistance, proinflammatory cytokines and a prothrombotic state. Treatment of the
metabolic syndrome involves appropriate risk assessment for potential future cardiac
events. The use of the Framingham risk assessment tool is helpful in predicting 10-year
risk of coronary heart disease and stratifying patients as to their need for intensive
treatment (Ingelsson, et al., 2007). According to the NCEP, measurements of adiposity
and lipid levels are reliable identifiers for those with insulin resistance, and they describe
what another group has termed “hypertriglyceridemic waist,” or a combination of
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elevated measurements of waist circumference and triglycerides that is associated with
increased cardiovascular risk (Tankó, Bagger, & Qin, 2005).
Metabolic syndrome has been linked to insulin resistance, abdominal obesity and
an unhealthy lifestyle. It has been estimated that if left untreated, those with metabolic
syndrome will experience complications such as insulin resistance and atherosclerosis
within 15 years, which presents time for intervention. Treatment of early symptoms may
help to alleviate poor health outcomes and perhaps lessen the burden on health care costs.
The most common treatments for metabolic syndrome are therapeutic lifestyle changes
(TLC) (i.e. diet and exercise), weight loss, and medication (Grundy et al., 2005).
Individuals with hyperlipidemia require initiation of therapeutic lifestyle changes
including weight reduction, reductions in saturated fat and cholesterol in the diet,
increased intake of soluble fiber (10–25 g/day) and plant stanols/sterols (2 g/day) and
increased physical activity. First-line treatment for obesity is behavior modification,
including a low-calorie, low-fat diet with calorie reduction of 500–1000 kcal/day,
increased activity to 30 minutes per day most days of the week and behavioral counseling
to improve stimulus control, reward positive lifestyle changes, and provide social
support.
Pharmacologic therapy for obesity is warranted after an adequate trial of
behavioral modifications including diet, exercise, and behavioral therapy have failed to
yield appropriate weight loss goals (Levy, Finch, Crowell, Talley, & Jeffery, 2007). Both
orlistat and sibutramine are effective in inducing modest weight losses in conjunction
with behavioral therapies. Surgical procedures for obesity may be considered for
individuals with a BMI ≥ 40 who have obesity-related co-morbid conditions such as
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hypertension, impaired glucose tolerance, diabetes, hyperlipidemia or obstructive sleep
apnea, and where other options for weight loss have failed (Orchard et al., 2005).
Cholesterol management is a cornerstone of therapy for patients at risk for heartrelated events, with the focus of interventions aimed at reducing LDL-C concentrations.
The reduction of LDL-C has been proven to have a significant impact in reducing the
morbidity and mortality associated with cardiac disease. In addition to LDL-C reduction,
results from the Framingham Heart Study and other trials have demonstrated that event
risk is also independently associated with varying concentrations of HDL-C (Obunai et
al., 2007). With this in mind, the initial treatment protocol for cardiovascular disease
centers on TLC, guidelines that prompt the patient to assess and modify eating and
exercise habits. The goal of treatment is to reach and maintain ideal body weight, bring
blood pressure to within normal limits, and reduce the impact that lifestyle choices have
on total and LDL-C (Emili et al., 2007).
Pharmacologic Measures for Treatment of Metabolic Syndrome. Drug therapy,
typically a statin, is recommended when low-density lipoprotein cholesterol (LDL-C) is
not lowered sufficiently by lifestyle modifications. Treating non-lipid risk factors
includes treating hypertension and using aspirin to reduce the prothrombotic state in
patients with chronic heart disease (CHD). Insulin resistance, which is usually indicated
by an impaired fasting glucose, is best improved by weight loss, a heart-healthy diet, and
regular physical activity (Grundy et al., 2005).
The ATP III (2005) recommends medication therapy for LDL levels > 160
mg/dL, and patients at moderately high risk may consider a treatment goal of LDL < 100
mg/dL. Statins are usually first-line treatment for hyperlipidemia, although individuals
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with metabolic syndrome frequently have low high-density lipoprotein cholesterol (HDLC) and hypertriglyceridemia that may require additional medication with niacin or
fibrates if statin therapy is unable to reduce their lipoprotein profile adequately.
Nonpharmacologic Measures for Treatment of Metabolic Syndrome. Lifestyle
intervention, inducing a modest BMI and waist reduction, can substantially affect the
prevalence of metabolic syndrome and its components (Bo et al., 2007). Lifestyle
modification is a primary treatment modality for all of the parameters that make up
metabolic syndrome. Such modifications include changes in both dietary and exercise
behaviors. These lifestyle interventions appear to be most effective in reducing waist
circumference and blood pressure with relatively little effect on HDL-C and lipid
abnormalities (Katzmarzyk et al., 2006). The Diabetes Prevention Program (DPP)
showed that intensive lifestyle changes resulting in losing 5–7% of weight through
increased physical activity and a reduced calorie diet prevented or delayed the onset of
type 2 diabetes by 58% in people at high risk for the disease. The DPP also showed that
metformin, an oral diabetes drug, reduced the onset of type 2 diabetes by 31% (Diabetes
Prevention Program Research Group [DPPRG], 2002).
Therapeutic Lifestyle Changes (TLC) Diet. Originally outlined in the American
Heart Association’s Step 1 and Step 2 diets (Lichtenstein et al., 2002), the TLC diet
consolidates the key elements into one set of guidelines. The primary diet message has
remained basically unchanged over several decades: choose a diet rich in fruits,
vegetables, whole grains, poultry, fish, and non-fat dairy foods, and limit intake of red
meat, full-fat dairy foods and other high-fat animal products. The updated guidelines
expand on what types and how much fat should be included in a “heart healthy” diet and
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propose adding fiber and plant sterols to the diet as additional cholesterol-lowering
strategies. “Thus, a comprehensive strategy to decrease cardiovascular morbidity and
mortality should include primarily a cardioprotective diet” (de Lorgeri, M. et al, 1999, p.
785). It should also be associated with other means aimed at reducing modifiable risk
factors.
Nutrition that leads to at least a 7–10% decrease in weight or BMI of hopefully <
25 kg/m2, which includes at least five servings of fruits and vegetables daily, and has a
negative energy balance on average of 500 calories per day is sufficient to have a
significant impact on the components of the syndrome and the prevention of development
of diabetes (DPPRG, 2002). TLC diet guidelines limit the intake of saturated fat (found in
animal fats and tropical oils) and trans fat (hydrogenated or hardened), vegetable fat
found in margarine and many types of cookies, crackers, and other snack foods. Both
types of fat have been shown to raise LDL-C. On the other hand, liquid or soft
polyunsaturated fats (vegetable oil, soft margarine) and monounsaturated fats are
associated with lower LDL-C levels. The most common sources of monounsaturated fats
in the U.S. diet are olive oil, canola oil, and nuts. In addition, the TLC guidelines advise
consumers to consider using a stanol- or sterol-containing spread to further lower LDL-C.
Patients are also advised to increase their intake of soluble fiber, either from supplements
such as Metamucil or fiber-rich foods like oatmeal, beans, and apples (Lichtenstein et al.,
2002) (see Table 2.3).
Mediterranean diet: Inspired by the low incidence of cardiovascular disease in
Mediterranean countries, proponents of the Mediterranean diet recommend high intakes
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of unsaturated fats (olive oil, nuts, fatty fish), fruits, vegetables, legumes, and whole
grains (Estruch et al., 2006).
Dairy products, eggs, poultry, and fish are eaten a few times per week, while red
meat and sweets are eaten sparingly. Many small studies suggest the Mediterranean diet
can reduce both cardiovascular risk and overall mortality. A 2005 cohort study of more
than 74,000 healthy Europeans over 60 years of age revealed that those eating a
Mediterranean-style diet had a significantly longer life expectancy than those following
other dietary patterns. A three-month trial comparing two versions of the Mediterranean
diet (one with olive oil, the other with nuts) with a low-fat AHA diet reported reductions
in CVD risk with the Mediterranean diet (Trichopoulou, 2005). Both Mediterranean
groups showed significant improvements in blood pressure, blood glucose, cholesterol:
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HDL ratio, and HDL levels, compared with the low-fat group. The Mediterranean diet
with nuts also showed decreases in total cholesterol and triglycerides (McMillan-Price,
Petocez, & Atkinson, 2006).
The TLC diet and Mediterranean-type diets have been recommended for the
treatment of metabolic syndrome as they seem to be effective in promoting long-term
adherence. Since patients with metabolic syndrome may differ in their clinical picture,
their responses to different dietary approaches, treatments are best individualized
(Melanson, 2008). While some of the factors that predict heart disease risk (including
age, gender, and family history) are not variable, progression of most types of heart
diseases can be modified by lifestyle choices.
Diet counseling. A Cochrane Review was revised in 2007 on the effects of dietary
advice given by a dietitian compared with another health professional or the use of selfhelp resources in reducing blood cholesterol in adults (Thompson et al., 2003). This study
assessed the effects of providing dietary advice to healthy adults in order to produce
improvement in their diets over a sustained period of time and examined whether dietary
improvement would reduce the risk factors associated with heart disease. They studied 38
trials in which 17,871 healthy adults were randomly assigned to receive dietary advice or
no dietary advice.
The dietary improvements recommended to the people in the intervention groups
centered largely on the reduction of salt and fat intake and an increase in the intake of
fruit, vegetables, and fiber (Thompson et al., 2003). Advice was delivered in a variety of
ways, including one-to-one contact, group sessions, and written materials. There were
variations in intensity of intervention, ranging from one contact per study participant to
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50 hours of counseling over 4 years. The duration of the trials ranged from 3 months to 4
years, with a median follow-up period of 10 months. Participants receiving advice from
dietitians experienced a greater reduction in blood cholesterol than those receiving advice
only from doctors (-0.25 mmol/L [95% CI, -0.37, -0.12 mmol/L]). There was no
statistically significant difference in change in blood cholesterol between dietitians and
self-help resources (-0.10 mmol/L [95% CI, -0.22, 0.03 mmol/L]). No statistically
significant differences were detected for secondary outcome measures between any of the
comparisons with the exception of dietitian versus nurse for HDL-C, where the dietitian
group showed a greater reduction (-0.06 mmol/L [95% CI, -0.11, -0.01]) and dietitian
versus counselor for body weight, where the dietitian group showed a greater reduction (5.80 kg [95% CI, -8.91, -2.69 kg]) (see Figure 2.1).
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There were some problems with this dietary review. First, according to the
inclusion/exclusion criteria, studies were not examined for medical nutritional therapy
versus other types of counseling. Medical nutritional counseling by a dietician includes
an individualized approach with at least one follow-up visit. Second, studies of
nutritionists were included, addressing the effectiveness of counseling given by a
registered dietitian who has received education via an American Dietetic Association
(ADA) accredited program and internship. Studies included in the Cochrane Review were
of a variety of individuals, including those with normal cholesterol values and not
specifically metabolic syndrome. Finally, the analysis was based on a limited number of
studies, some of which were of dubious quality, and some that may not have met the
inclusion criteria on a drop-out of approximately 20%.
Gami et al (2007) found 37 eligible studies that included 43 cohorts (from 1971
to 1997) and 172,573 individuals. Meta-analysis showed metabolic syndrome had a
relative risk (RR) of cardiovascular events and death of 1.78 (95% confidence interval
[CI] 1.58 to 2.00). The association was stronger in women (RR 2.63 vs. 1.98, p =
0.09) and in studies using factor analysis or the World Health Organization definition
(RR 2.68 and 2.06 vs. 1.67 for National Cholesterol Education Program definition and
1.35 for other definitions; p = 0.005). Cardiovascular events were about 33% higher for
women than men, according to seven studies that provided separate risk analyses for both
sexes. As part of the study, investigators did a separate meta-analysis of studies that
simultaneously adjusted for metabolic syndrome and its components. The relative risk
was 1.54 (95% CI 1.32-1.79). Women should be aware that they are at higher risk. “We
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generally think of men having a higher risk of CVD, but with the metabolic syndrome, it
appears women have a higher risk relative to men,” Gami et al. stated (2007, p. 412).
Dansinger (2007) in a meta analysis of 46 trials of dietary counseling revealed a
maximum net treatment effect of -1.9 (95% CI, -2.3 to -1.5) BMI units (approximately 6%) at 12 months. These studies were identified through a previously published
systematic review: MEDLINE and the Cochrane Central Register of Controlled Trials
from 1997 through July 2006. The authors included only weight loss studies with a
dietary component. Different analyses suggested that calorie recommendations,
frequency of support meetings, inclusion of exercise, and diabetes may be independent
predictors of weight change. Studies were generally of moderate to poor methodological
quality. They had high rates of missing data and failed to explain these losses.
Franz (2008) identified randomized controlled trials (RCTs) that evaluated weight
loss interventions in overweight or obese adults and had >1 year follow-up. Eighty RCTs
(n=26 455, mean age 23–69 y, 0–100% men) met the selection criteria. At baseline, mean
weight was 77–131 kg and mean body mass index was 29–43 kg/m2. The interventions
included advice only (28 RCTs), exercise (6 RCTs), diet (51 RCTs), diet plus exercise
(17 RCTs), meal replacements (7 RCTs), very-low-energy diet (11 RCTs), orlistat (13
RCTs), and ibutramine (7 RCTs). No RCT on bariatric surgery was found. Study duration
ranged from 12 to 60 months. Overall patient follow-up was 69%. For most
interventions, maximum weight loss occurred early in the study (pooled mean weight loss
at 6 mo was 0.7 kg for advice only, 2.4 kg for exercise, 4.9 kg for diet, 7.9 kg for diet
plus exercise, 8.2 kg for sibutramine, 8.3 kg for orlistat, 8.6 kg for meal replacements,
and 18 kg for very-low-energy diet), with some re-gain over time. Except for advice only,
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mean weight did not completely return to baseline level by study end. Meta-analysis
showed that reduced-energy diets, with or without exercise, resulted in more weight loss
than advice alone. The results of the comprehensive review by Franz et al. (2007)
support guidelines for weight loss: a multifaceted approach of diet, exercise, and
behavioral therapy, with the addition of medication if the initial approach is not effective
after 6 months. As expected from clinical experience, early weight loss was followed by a
plateau. Weight re-gain occurred with all interventions, including after discontinuing the
weight loss medications. It is important to note that the long-term safety of these
medications is unknown. On average, participants in diet and exercise, medication, or
meal replacement interventions maintained a 4–8% weight loss at >1 year, approximating
the 5–10% weight loss advised for health benefits.
Reviews of the significant meta-analyses identified in this project are listed in
Table 2.4. While all of these findings are applicable to clinical practice, clinicians can use
this evidence to motivate patients when counseling them to reduce risk factors associated
with metabolic syndrome. Medications and meal replacements, although more effective
than diet alone, are not recommended or accessible for all patients, especially in the
uninsured population. They also must be accompanied by diet, exercise, and behavioral
therapy. The evidence demonstrating the effectiveness of specific interventions in
preventing cardiovascular disease in this population with metabolic syndrome is limited.
This project examines the evidence for the use of nutritional interventions in addressing
the modifiable risk factors.

Table 2.4 Meta-Analysis Evaluation
Question
Will the answer if true, have a direct bearing on the health of patients?
Is the outcome or topic something that patients/clients/population groups would care about?
Is the problem addressed in the review one that is relevant to practice?
Will the information, if true, require a change in practice?
Was the question for the review clearly focused and appropriate?
Was the search strategy used to locate relevant studies comprehensive? Were the databases
searched and the search terms used described?
Were explicit methods used to select studies to include in the review? Were inclusion/exclusion
criteria specified and appropriate? Were selection methods unbiased?
Was there an appraisal of the quality and validity of studies included in the review? Were appraisal
methods specified, appropriate, and reproducible?
Were specific treatments/interventions/exposures described? Were treatments similar enough to be
combined?
Was the outcome of interest clearly indicated? Were other potential harms and benefits considered?
Were processes for data abstraction, synthesis, and analysis described? Were they applied
consistently across studies and groups? Was there appropriate use of qualitative and/or quantitative
synthesis? Was variation in findings among studies analyzed? Were heterogeneity issued
considered? If data from studies were aggregated for meta-analysis, was the procedure described?
Are the results clearly presented in narrative and/or quantitative terms? If summary statistics are
used, are levels of significance and/or confidence intervals included?
Are conclusions supported by results with biases and limitations taken into consideration? Are
limitations of the review identified and discussed?
Was bias due to the review’s funding or sponsorship unlikely?

Cochrane
Review
2007
Yes
Yes
Yes
Yes
Yes
Yes

Gami et
al.,
2007
Yes
Yes
Yes
Yes
Yes
Yes

Dansinger
et al.,
2007
Yes
Yes
Yes
Yes
Yes
Yes

Franz et
al.
2007
Yes
Yes
Yes
Yes
Yes
Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

No

No

Yes
???

Yes
Yes

Yes
No

Yes
No

Yes

Yes

Yes

Yes

No

Yes

No

No

Yes

Yes

Yes

Yes
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"The time has come to apply to diet research the same level of evidence required
for other interventions. We believe that indications or claims made for weight loss or
health improvement via diet—whether made by authors, the government, or
associations—must be supported by 3 types of evidence: proof that the diet provides
essential nutrients in actual patients, efficacy studies, and randomized, controlled trials
with clinical events as end points....Until then, the public will continue to be subject to
speculation and potentially hazardous extrapolation from putative biological surrogates to
clinical outcomes" (Yancy, Westman, French, & Califf, 2003, p. 14).
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Chapter Three: Methodology
This chapter includes a description of the design, setting and sample for the
project. This is followed by a discussion of the methods and procedures for the study,
including the protection of human subjects.
Study Design
This project was the implementation of an evidence-based practice change
incorporating an intensive dietary program for patients with metabolic syndrome and an
evaluation of the effect of that change on lipoproteins, glucose, blood pressure, weight,
and waist circumference. This study was a one-group before-and-after design, with
baseline data obtained on patients prior to the practice change. The study ran for six
months.
Setting
The setting for the study was a medical practice in a large city in the southeastern
U.S. The practice had both physicians and nurse practitioners providing primary care
services. The clinic serves uninsured residents of the county who have an income level of
not more than 150% of federal poverty criteria. The clinic patient demographics were as
follows: Caucasian (44%), African American (30%), Asian American (11%),
Latino/Hispanic (9%), and 5% classified as other. The demographics for the county
include: Caucasian (64.4%), African American (29.8%), Latino/Hispanic (6.3%) and
1.8% classified as other (VIM-JAX, 2008 Data). There were approximately 5,000
patients in this practice, approximately 22% of whom have metabolic syndrome.
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Sample
This project was offered to all new patients of the practice who met the criteria for
metabolic syndrome. The subjects were eligible for participation in this study if they met
three or more of the five NCEP-ATP III criteria for identifying metabolic syndrome
(Grundy et al., 2005):
1. Waist circumference > 35 in. for women and > 40 in. for men.
2. Blood pressure with either diastolic > 134 or systolic > 84 mm HG.
3. Fasting triglycerides > 150 mg/dL.
4. HDL-C < 50 mg/dL for women and < 40 mg/dL for men.
5. Fasting blood glucose ≥ 100 mg/dL or the presence of type 2 diabetes.
Patients who already had type 2 diabetes or hypertension were able to be included
in this study. Exclusion: Participants who were younger than 21 years of age were
excluded from this project. If a person had a history of medical noncompliance
documented in the medical record, they were excluded.
Methods
Data collection for this study took place over a period of six months, beginning in
early July 2008 and ending in December 2008. Subjects were identified by the clinic
medical director and clinical director as potential participants. The subjects were new to
the practice with the diagnosis of metabolic syndrome based on the ATP III guidelines.
Once the diagnosis was verified by chart review, the researcher spoke to the participants
to thoroughly explain the research and they were told they could terminate the interview
at any time if they so desired. After the explanation was completed, the participant was
given the opportunity to ask questions. Once written consent to participate was obtained,
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participants were counseled by the researcher or the clinic director regarding the diet
program. The patients were told it would take approximately three one-hour sessions with
the graduate dietary intern over a six-month period.
Data Collection
Blood pressure, weight, waist circumference, and exercise participation were
measured on entry into the study. A dietary assessment was performed using a 24 hour
dietary recall. Fasting blood levels were determined for lipoproteins and blood glucose.
These parameters were assessed again at 3 months and 6 months.
Blood pressure. Blood pressure was measured by the graduate dietary intern who
had been individually trained following the guidelines published by the American Heart
Association (Pickering et al., 2005). Blood pressure was recorded in the sitting position
using the right arm to the nearest 2 mmHg with a sphygmomanometer. Two readings
were taken 5 min apart, and the mean of the two was taken as the blood pressure.
Weight. Weight was evaluated in pounds using the same DetectoTM office scale.
Weight was measured by the graduate dietary intern with the patient fully dressed and
without shoes. Although the standard is that calibration of the scale within the last year
resulted in scales with significantly more precise readings (p<0.001) (Stein, Haddock,
Poston, Catanase, & Spertus, 2005), for the purposes of this study, monthly calibration
was done
Waist circumference. Waist girth was measured as the narrowest circumference
between the bottom of the rib cage and the iliac crest by using an unstretched tape
measure (Katzmarzyk et al, 2006). Waist circumference was measured by the graduate
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dietary intern using the same tape measure for each patient. Waist circumference was
measured at the level of the umbilicus with clothing from around the waist removed.
Lipoproteins and fasting glucose. Blood samples from all individuals were
obtained after a 12-hour fasting period. Samples were analyzed by Consolidated
Laboratories. Consolidated Laboratory Services is a comprehensive laboratory that
services medical facilities throughout northeast Florida and southeast Georgia. The
laboratory is subject to stringent internal and external quality control programs. They
have a planned systematic process for monitoring, evaluating, and continually improving
the quality of laboratory services.
Intervention
Participants continued to receive the usual primary care at the clinic. Additionally
they received dietary counseling strategies designed to prevent Type 2 diabetes and
cardiovascular disease by the achievement and maintenance of normal body weight and
reduction of abdominal obesity, blood lipid values, fasting blood glucose levels, and
blood pressure. Each participant was counseled by a graduate nutrition intern from the
University of North Florida regarding the Mediterranean and TLC diets. The best dietary
pattern contains elements from each of the diets described here: an emphasis on wholegrain carbohydrates, unsaturated fats, fruits, vegetables, legumes, and lean protein, with
reductions in saturated and trans fats and refined carbohydrates. Participants were
counseled and assisted to choose foods from the two diets that would fit in with their
personal likes and lifestyles because the most important process is finding a diet the
person can adopt for the long term in combination with regular exercise (Zivkovic,
German, & Sanyal, 2007).
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Participants took part in three individualized nutrition counseling sessions
scheduled at 4-6 weeks intervals (see Appendix C). The initial session was used to obtain
a 24-hour diet recall, occupation, living situation and current life situation. The session
topic, “10 Steps to a Healthy Lifestyle,” reviewed the importance of fiber, reading food
labels, importance of exercise, pedometer use, proper portion sizes, low-fat food choices
and how to complete a food journal.
The second session included information on eating out, healthy snacking, and
omega-3 fatty acids. Examples of healthy entrees and snacks were given. Subjects were
given samples of whole grain cereal.
Session three focused on Internet resources. The websites provided were for
healthy recipes, motivation, exercise, healthy living tips, and nutrition databases. To
encourage intake of water and calorie-free fluids subjects were given a water bottle.
Each subject was given lab order form and instructed to get the blood drawn (fasting) at
the beginning of the week of their next appointment. During the third session a final 24hour food recall was obtained. Results of new lab work were discussed and comparisons
were made from the initial visit.
Protection of Human Subjects
Permission to conduct this study was obtained from the investigator’s project
committee, the Institutional Review Board for The University of North Florida, and the
executive board of the clinic. Subjects were provided essential information for informed
consent and signed a consent form. The benefit-risk ratio was assessed for this study,
indicating important benefits and minimal risk.
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Chapter Four: Results
This chapter describes the study population using mean scores and frequency of
the variables. Analyses were executed using SPSS statistical software (version 16.0,
2007, Chicago, IL) with statistical significance determined at p≤.05. Data were analyzed
using descriptive statistics and non-parametric t-tests to determine changes in metabolic
syndrome indicators from pretest to posttest. Pearson correlation coefficients were
calculated to quantify the associations among variables.
Demographic Data
Twenty-three individuals signed consent to participate in the study, but only 19
completed the study. There were no significant differences in either demographic or
study variables at the initial data collection point between those who completed the study
and those who did not. Data analysis is based on the 19 who completed the study.
Subjects were between 29 and 58 years-of-age (M=45.21, SD=8.68); predominately
female (n=16, 84.21%); and predominately Caucasian (n=13, 68.42%) with 4 (21.05%)
African-Americans and 2 (10.53%) Hispanics. Fifteen (78.95%) of the participants
smoked cigarettes. Demographic variables of the sample were not significantly different
from the demographics of patients in the clinic. Table 4.1 presents the baseline measures
related to body measurements.
Dietary Adherence
Examination of the 24-hour diet recalls at baseline and six months revealed no
significant difference in any of the dietary variables (see Table 4.2)
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Table 4.1
Baseline Measures of Sample (n = 19)
Participants
Mean
Waist Circumference
46.43
Body Weight
BMI

SD
+6.95

252.22

+58.07

40.9

+9.76

Table 4.2
24- hour Diet Recall (n=13)
Food Group
(recommended # of
servings)
Bread, Cereal, Rice, and
Pasta (6-11 servings)
Vegetables (3-5 servings)
Fruits (2-4 servings)
Milk, Yogurt, and Cheese
(2-3 servings)
Meat, Poultry, Fish, Dry
Beans, Eggs, and Nuts
(2-3 servings)
Fats, Oils, and Sweets
(use sparingly)

Average #
Servings at
Baseline
4.0

Average # Servings
After 6 Months

Change

3.31

-0.69

1.54
1.46
1.85

1.31
1.46
2.31

-0.23
0.0
+0.46

3.62

3.23

-0.39

2.85

2.69

-0.16

The data from the participants who completed the 24 hour diet recall was only
thirteen of the nineteen patients in the study. We relied on self-reported dietary intake,
but we validated the dietary assessment individually to minimize the amount of missing
data. Finally, one might argue that the unique nature of the clinic in this study makes it
difficult to generalize the results to clinic setting. However, we believe that similar
strategies to maintain adherence could be applied elsewhere.
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Comparison of Metabolic Syndrome Indicators Before and After Dietary Intervention
Because not all participants returned to the clinic for data collection at the 3month session, only baseline and 6-month data were consistently available for 19
participants. Changes were measured and calculated by subtracting the baseline value
from the 6-month value. The mean change in metabolic syndrome indicators for each
variable indicates that the study group had significantly improved systolic and diastolic
blood pressure, total cholesterol, fasting glucose, triglycerides, HDL and LDL levels
compared to the group from baseline to post-intervention as illustrated in Table 4.3.
Table 4.3
Study Group Mean Diagnostic Indicators from Baseline to Post-Intervention (n=19)
Data (Mean)
Initial

6 Months

Change

252.2

261.78

9.58

Body mass index (kg/m )

40.9

42.37

1.47

Waist Circumference (in)

46.43

46.7

0.27

Fasting Glucose (mmol/L)

98.87

95.92

-5.08

Systolic blood pressure (mm Hg)

136.74

127.11

-13.89

Diastolic blood pressure (mm Hg)

93.22

81.67

-12.11

147.57

129.47

-5.07

39.30

43.67

3.47

121.00

113.47

Weight (pounds)
2

Triglycerides* (mmol/L)
High-density lipoprotein(mmol/L)
Low-density lipoprotein
(mmol/L)

-6.13

Pearson correlation analyses revealed no significant association between the
demographic variables of age, race, gender, and smoking with any of the outcome
variables themselves, or with the post-intervention change. Participants varied in the
number of dietary counseling sessions they attended. While 14 of the 19 participants
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(73.68%) had one or more visits, only 5 (26.32%) had more than three total visits. There
was no discernable pattern of association between the dose of the dietary intervention
(that is, the number of visits) and metabolic syndrome indicators.
Although the intent at the outset of the study was to hold medications constant, in
fact, three individuals (15.79%) had cholesterol-lowering medication changes and two
individuals (10.53%) had antihypertensive medication changes during the course of the
study. There was no significant association between the medication changes and the
metabolic syndrome indicators.
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Chapter Five: Conclusion
This chapter provides a discussion of the study findings relevant to the dietary
intervention and lessons learned in the process. Implications for evidence-based
practice and future research are also presented.
Discussion
The aim of this project was to determine whether dietary changes related to
nutrition counseling can improve the outcomes of patients with metabolic syndrome at
the Volunteer in Medicine Jacksonville Clinic (VIM-JAX) in Jacksonville, FL.
Additionally, age, gender, and baseline laboratory studies as predictors of weight loss
were explored. Diet has been shown to be a major contributor to metabolic syndrome in
susceptible individuals (Grundy et al., 2005). Among adults, the prevalence of obesity
and overweight has increased rapidly over the last 15 years to 65% and parallels the
increase in diabetes. The prevalence of metabolic syndrome increases with age and
varies by ethnicity, with Hispanics having the highest age-adjusted prevalence compared
with other ethnic groups. Hispanics currently represent over 14% of the total U.S.
population and have a projected growth to 25% of the total population by 2050 (Noel, S.,
Newby, P., Odrovas, J., & Tucker, K., 2009). Even though only 9% of the population at
VIM-JAX is Hispanic, 21% of the participants were in this group.
Results of the study showed marked improvement in all of the variables for
hypertension and dyslipidemia (blood pressure, FBS, HDL, LDL and triglycerides). On
the other hand, both BMI and weight increased overall in this study group. Multiple
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attempts to identify correlation between these variables and dietary intervention were
unsuccessful. Also, most of the patients (94%) were either on a lipid lowering agent
and/or antihypertensive throughout the study which may have affected the outcomes.
This study failed to support the hypothesis that TLC dietary intervention will improve
metabolic syndrome parameters in an uninsured population. Most of the individuals
affected by metabolic syndrome are overweight, therefore dietary treatment should be
primarily focused on weight reduction. Therefore a diet to treat individuals with
metabolic syndrome will have some general characteristics, but will have specific
properties to take into account the abnormalities present in that individual patient (i.e.
hypertension and dyslipidemia). “In the absence of clear scientific evidence, individuals
with metabolic syndrome will continue to be treated with multiple drug prescriptions that
mitigate the symptoms, but are inadequate to treat the disease” (Riccaradi & Reveilles,
2000, p. S147).
Limitations
Lack of uniform definition. There were many limitations to this study that should
be noted. First, the lack of a uniform definition of the Metabolic Syndrome was a
limitation for this study. Although the Metabolic Syndrome is a well recognized clinical
phenomenon, there is no accepted definition, and the physiological changes in childhood
make the definition particularly difficult to classify. Johnson and Weinstock (2006)
have shown the NCEP ATP III criteria to have definite flaws. “First, the 5 criteria and
the cutoffs appear to be arbitrary and not evidence based. Second, the risk factor values
are continuous and must be considered as such, not just as present or absent. The fact that
CVD risk increases with increasing blood glucose levels, systolic blood pressure, and
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LDL cholesterol values has been well documented. Third, important risk factors such as
LDL cholesterol, cigarette smoking, family history, and age are not included, limiting the
usefulness of the metabolic syndrome in predicting CVD risk” (p. 1616). The metabolic
syndrome has been defined in several ways and thus cannot be considered a precise
diagnosis.
Recently (2009), five major scientific organizations – the International Diabetes
Federation (IDF), the (NHLBI), the AHA, the World Heart Federation (WHF), the
International Atherosclerosis Society (IAS), and the International Association of the
Study of Obesity (IASO) – have just released a joint interim statement that represents a
giant leap toward a unified definition of the metabolic syndrome. Individuals who meet at
least 3 of 5 clinical criteria will be diagnosed as having the condition; presence of none of
these criteria is mandatory. Specific cut points are defined for all criteria, except elevated
waist circumference, which must rely on population and country-specific definitions
(Alberti et al., 2009).
Weight loss limitations. The weight loss of the subjects may not reflect fat mass
loss. Obesity was measured by BMI and weight. This measure was used because of its
simplicity, economical and ease of use for the clinician, however, true fat mass was not
assessed. Weight loss generally involves the loss of both fat and lean mass and it is
anticipated that fat mass loss contributes to improvements in Metabolic Syndrome
markers.
Multiple providers. Second, study participants were seen by different graduate
dietary interns who rotated throughout the semester. Based on scheduling conflicts, the
study participant would not see the same intern for follow-up appointments. In addition,
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VIM-JAX uses multiple primary care providers who followed these patients. Rapport
with the patient may be better with consistent providers. Beutow (2003) cautioned
“provider continuity will not happen if there is a lack of consistency in who attends with
or for the patient during successive visits” (p. 509). He also described how continuity of
care can be weakened because the clinician may be hindered from providing a “sustained
partnership” and having an ongoing sense of responsibility to the patient.
Use of graduate nutrition students. Because graduate nutrition practitioners are
educated in a wide range of practice settings, it is difficult to differentiate the varying
levels of expertise. There may be a lack of systematic instruction, counseling and
coaching system caused by the use of multiple interns at VIM-Jax that impacted on the
ability to promote effective diet change. There is a need for more consistent training of
the graduate nutrition interns along with the primary care providers for use of specific
and consistent messaging via counseling or motivational interviewing and coaching.
Lack of computer support. Originally, the study was designed to use a dietary
analysis computer program. The Self-Efficacy for Healthy Eating Scale (Baughman et al.,
2003) measures healthy eating self-efficacy. The instrument consists of a 20-item likert
scale with a reliability α coefficient of 0.95 and was designed to measure participant
ability to eat a healthy diet including eating more fruits and vegetables, eating less dietary
fat, and eating smaller portions. Food records of weekly intake were to be analyzed
using the Food Processor ™ computer program to provide mean dietary energy intake,
daily grams of fiber, percentage of calories from fat, saturated fat, protein, and
carbohydrates; and daily servings of fruits and vegetables. The Food Processor instantly
compares patient dietary intake against recommended nutrient standards, analyzing as
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many as 164 nutritional components. It includes a database of over 32,000 foods, recipes
and exercises and users can add an unlimited number of foods and modify existing foods
(ESHA research). Because of outdated and limited computer support at VIM-JAX, this
program was unavailable for use.
Scheduling conflicts. Finally, individuals who were recruited for the current study
had to attend the nutrition appointments within a specified time frame. Therefore, the
sample was limited to those who made and attended the appointments at VIM-JAX.
Because the study used UNF graduate nutrition interns, the students’ schedule was an
obstacle to providing choices in appointment times and dates for the study participants.
All of the nutrition classes were only offered on Fridays when classes were in session.
National data suggests that 12 million appointments in the primary care setting are not
attended each year, approximately 6.5% of the appointments made (Martin, Perfect, &
Mantle, 2005). This “no show” rate is likely to be higher in a primary care setting serving
predominantly indigent patients who have more barriers to attending appointments (i.e.,
transportation, work schedule, daycare).
Conclusion
Those with metabolic syndrome have significantly higher risks for developing
diabetes and cardiovascular disease. Public health experts estimate that billions of dollars
in medical costs are spent managing patients with metabolic syndrome each year in the
United States. Morbidity and mortality stemming from obesity and metabolic syndrome
has reached epidemic proportions. Aggressive treatment of metabolic syndrome is
critical for the health of the world’s population. More research is necessary to identify the
components that are most effective for weight loss especially in the primary care setting.
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Specifically, evidence based studies are needed with this population comparing
medical and pharmacotherapy versus more general dietary/exercise interventions. The
issue of the confounding variables related to medication vs. diet and different outcomes
based on adherence to one or the other and subsequent outcomes needs more research.
Twenty eight percent of the participants in the study were either on an antihypertensive or
lipid lowering agent or both.
The optimal management of patients at high risk for cardiovascular disease
requires both assessment and treatment of the modifiable cardiometabolic risk factors
established by evidence-based guidelines. “The ultimate utility of even considering
metabolic syndrome may simply be to provide patients and clinicians a framework in
which to discuss the importance of multiple risk factors and interventions, especially if
the patient has no symptoms and therefore is likely to be unmotivated and more likely to
choose pharmacotherapy when ill than lifestyle changes before irreversible illness
occurs” (Stolar, 2007, p. 207).
Lifestyle changes are the most important element in helping patients stop the
progression of metabolic syndrome to cardiovascular disease. These are often the most
difficult patients for health care providers to manage. "Motivational interviewing" is
another useful strategy that can aid the provider when resistance is met or the challenge
to change seems burdensome. Motivational interviewing is a 3-step, therapeutic
approach that can assist providers in encouraging behavior change in their patients with
metabolic syndrome (West, DiLillo, Bursac, Gore, & Greene, 2007). Numerous studies
have shown that trust between a health care provider and a patient is one of the most
important elements contributing to a patient’s success (Beutow, 2003). Yet patients find
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it difficult to undertake the recommendations we ask of them. If we could identify
metabolic syndrome patients who are at risk of developing diabetes or cardiovascular
disease, we might be able to intervene earlier. By gaining skills to help motivate,
encourage, and support patients in successfully implementing lifestyle changes to
improve their health status, clinicians can enhance their patients’ wellness and begin
reducing the burden of cardiovascular disease in the U.S.
“The time has come to apply to diet research the same level of evidence required
for other interventions. We believe that indications or claims made for weight loss or
health improvement via diet—whether made by authors, the government, or
associations—must be supported by 3 types of evidence: proof that the diet provides
essential nutrients in actual patients, efficacy studies, and randomized, controlled trials
with clinical events as end points” (Yancy, et al., 2003, p. 14).
As clinicians, “if we could identify patient subgroups truly at risk of developing
diabetes or cardiovascular disease, we might be able to intervene earlier and more costeffectively, rather than screening and treating the general population” (Stolar, 2007, p.
206). The ultimate reason to identify metabolic syndrome may simply be to provide
patients and clinicians a framework in which to discuss the importance of multiple risk
factors and interventions. This is especially important if the patient has no symptoms and
therefore is likely to be unmotivated and more likely to choose pharmacotherapy than
lifestyle changes.

Appendix A: Critical Analysis Table: Review of the Evidence
Author
(Dates)
Brunner et al.
(2007)

Title

Type

N

Comments

Dietary advice

Cochrane Review

17,871
subjects

Gami et al.
(2007)

Metabolic
syndrome

37
studies,
172,573
subjects

Dansinger et
al. (2007)

Meta-analysis: The
effects of dietary
counseling

Franz et al.
(2007)

Weight-loss
outcomes: A
systematic review
and meta-analysis

Meta-analysis and
systematic review of
metabolic syndrome
and incidence of
cardiovascular events
Meta-analysis of the
effects of dietary
counseling compared
with usual care in
adults
Systematic review
to determine types of
weight-loss
interventions
that contribute to
successful outcomes
and to define expected
weight-loss outcomes
from the interventions

Dietary advice appears to be effective in bringing about
modest beneficial changes in diet and cardiovascular risk
factors over approximately 10 months but longer-term effects
are not known.
Evidence suggested metabolic syndrome increases risk of
cardiovascular events.
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clinical
trials,
11, 853
subjects
80 RCT
studies,
26,455
subjects

Compared with usual care, dietary counseling interventions
produce modest weight losses that diminish over time.

Reduced-energy diets, with or without exercise, promote
weight loss more than advice alone. Meal replacement and
weight-management drugs promote weight loss more than diet
alone. Regardless of intervention type, most weight loss
occurs in the first six months, with some weight re-gain
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Author
(Dates)
Nordmann et
al. (2006)

Title

Type

N

Comments

Effects of lowcarbohydrate vs.
low-fat diets on
weight loss

5 RCT
studies,
447
subjects

Low-carbohydrate, non-energy-restricted
diets appear to be at least as effective as low-fat, energy
restricted diets in inducing weight loss for up to one year

Galassi et al.
(2006)

Metabolic
syndrome and risk
of cardiovascular
disease: A metaanalysis

Meta-analysis
comparing the effects
of low
carbohydrate
diets without
restriction of energy
intake vs. low-fat diets
in individuals with a
BMI of at least 25
Meta-analysis
examining the
association between
the metabolic
syndrome and risk of
cardiovascular disease

This meta-analysis indicated that individuals with the
metabolic syndrome have a 61% increased risk of
cardiovascular disease compared to individuals without the
metabolic syndrome

Yamaoka &
Tango (2005)

Efficacy of
lifestyle education

21
Prospect
ive
cohort
studies,
78,769
subjects
9 RCT
studies,
10,461
subjects

Meta-analysis
evaluating the efficacy
of lifestyle education
for preventing type 2
diabetes in individuals
at high risk by metaanalysis of RCTs

Lifestyle education interventions of the studies varied widely.
This meta-analysis provided evidence of a relationship
between lifestyle education in high risk subjects and the
prevention of type 2 diabetes
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Author
(Dates)
AHRQ (2005)

Groeneveld et
al. (2008)

Title

Type

N

Comments

Screening for
metabolic
syndrome

Guideline using a
review of published
meta-analyses,
systematic reviews,
and systematic reviews
with evidence tables.

N/A

RCT

692
subjects

RCT

522
subjects

The recommendations were based primarily on sources such
as national guidelines and consensus statements written on
hyperlipidemia, hypertension, and diabetes mellitus by the
National Cholesterol Education Program Expert Panel, the
Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure, and Workgroup of the
American Diabetes Association. Guidelines and statements
were synthesized to make them applicable to the screening
and treatment of metabolic syndrome
By improving lifestyle, CVD risk may be lowered, yielding
benefits for both employee and employer. By improving
lifestyle, CVD risk may be lowered, yielding benefits for both
employee and employer. If proven effective, this lifestyle
intervention will be implemented on a larger scale within the
Occupational Health Services in construction industry
There is a significant reduction in the prevalence of metabolic
syndrome in the intervention group compared with the control
group, suggesting that lifestyle intervention may also reduce
risk of cardiovascular disease

RCT

375
subjects

Evaluating the
cost- effectiveness
of a lifestyle
intervention

Ilanne-Parikka
Effect of lifestyle
et al. (2008)
intervention on the
occurrence of
metabolic
syndrome
Bo et al.
Effectiveness of a
(2007)
lifestyle
intervention on
metabolic
syndrome

A lifestyle intervention based on general recommendations
was effective in reducing multiple metabolic abnormalities
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Author
(Dates)
Orchard et al.
(2005)

Title

Type

N

Comments

The effect of
metformin and
intensive lifestyle
intervention

RCT

1,711
subjects

Esposito et al.
(2004)

Effect of a
Mediterraneanstyle diet

RCT

180
subjects

Metabolic syndrome affected approximately 50% of the
participants in the Diabetes Prevention Program at baseline.
Both lifestyle intervention and metformin therapy reduced the
development of the syndrome in the remaining participants in
the study
A Mediterranean-style diet might be effective in reducing the
prevalence of the metabolic syndrome and its associated
cardiovascular risk

de Lorgeril et
al. (1999)

Mediterranean diet, RCT
traditional risk
factors

605
subjects

There is reduced risk of CHD mortality due to Mediterranean
diet

Lutsey et al.
(2008)

Dietary intake and
the development of
metabolic
syndrome
Translating the
diabetes prevention
program into an
urban medically
underserved
community

Prospective
multicenter cohort
study

9,514
subjects

The consumption of a Western dietary pattern, meat, and fried
foods promotes the incidence of metabolic syndrome, whereas
dairy consumption provides some protection

Prospective
intervention study

573
subjects

Adults in an urban medically underserved community can
decrease their risk for type 2 diabetes and CVD through
participation in a group lifestyle intervention, and short-term
sustainability is feasible

Seidel et al.,
(2008)
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Author
Title
(Dates)
Katzmarzyk et The importance of
al. (2006)
waist
circumference in
the definition of
metabolic
syndrome
Bonora et al.
Carotid
(2003)
atherosclerosis and
coronary heart
disease in the
metabolic
syndrome
Osei et al.
Is glycosylated
(2008)
Hemoglobin A1C a
surrogate for
metabolic
syndrome
Dilley et al.
Association of
(2007)
A1C with
cardiovascular
disease and
metabolic
syndrome
Mendoza et
Dietary energy
al.
density is
(2007)
associated with
obesity and the
metabolic
syndrome

Type

N

Comments

Prospective cohort
study

20,789
subjects

Waist circumference is an important component of metabolic
syndrome; however, the IDF requirement of an elevated waist
circumference warrants caution given that a large proportion
of men with normal waist circumference have multiple risk
factors and an increased risk of mortality

Prospective
population-based
survey

888
subjects

Subjects with the metabolic syndrome by WHO criteria had
an increased five-year incidence and progression of carotid
atherosclerosis

Cross sectional

219
subjects

Measuring random HbA1c levels in African American
patients serves as a surrogate of metabolic syndrome

Cross sectional

1,620
subjects

In Asian Indians with normal glucose tolerance, A1C showed
an association with most CVD risk factors, the metabolic
syndrome, and CAD

Cross sectional

9,688
subjects

Dietary energy density is an independent predictor of obesity,
elevated fasting insulin levels, and the metabolic syndrome in
U.S. adults
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Author
(Dates)
Panagiotakos
et al.
(2004)

Title

Type

N

Comments

The impact of
Cross sectional
3,042
Decreased risk of having the metabolic syndrome due to
lifestyle habits on
subjects Mediterranean diet
the prevalence of
the metabolic
syndrome
Vaidya et al.
Defining the
Cross sectional
6,781
Metabolic syndrome was associated with greater insulin
(2007)
metabolic
subjects resistance and was compatible with two of three “syndrome”
syndrome
constructs tested
Strazzullo et
Diagnostic criteria Comparative
933
A five-fold difference in the prevalence of MS resulted from
al. (2008)
for metabolic
subjects the use of different diagnostic criteria
syndrome
Dallongeville Household income Comparative
1,695
Limited household income, which reflects a complex
et al. (2005)
is associated with
subjects unfavorable social and economic environment, may increase
the risk of
the risk of metabolic syndrome in a sex-specific manner
metabolic
syndrome
Abbreviations: A1C = ; BMI = body mass index; CAD = ; CHD = ; CVD = cardiovascular disease; RCT = randomized controlled trials.
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Appendix B: Data Collection Sheet
NCEP-ATP III Definition
n
Age (years)
Men (%)
Body mass index (kg/m2)
Waist, men (cm)
Waist, women (cm)
Glucose (mmol/L)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Triglycerides* (mmol/L)
High-density lipoprotein(mmol/L)
Low-density lipoprotein (mmol/L)
Smokers

Data
Initial

3 Months

6 Months
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Appendix C: Dietary Counseling Sessions

Survey instrument deleted, paper copy available upon request.
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Survey instrument deleted, paper copy available upon
request.
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Survey instrument deleted, paper copy available upon
request.
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Survey instrument deleted,
paper copy available upon
request.
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Survey instrument deleted, paper copy available upon request.
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Survey instrument deleted, paper copy available upon request.
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Survey instrument deleted, paper copy available upon request.
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Survey instrument deleted, paper copy available upon request.
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Survey instrument deleted, paper copy available upon request.
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Survey instrument deleted, paper copy available upon request.

62

Survey instrument deleted, paper copy available upon request.
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